ImpactNetwork

IQVIA (our parent company) has teamed up with AstraZeneca to speed up studies of a potential COVID-19 vaccine candidate. More: https://www.reuters.com//astrazeneca-ties-up-with-iqvia-to

IQVIA (NYSE: IQV), a leader in Human Data Science, today announced its new technology-enabled COVID-19 Trial Matching Tool at c19trials.com, which is one of the world’s first online platforms that matches individuals with specific COVID-19 studies to accelerate clinical research projects. More: https://www.iqvia.com//iqvia-launches-first-technology-ena

https://www.iqvia.com//virtual-trials-a-more-direct-path-t

#worldalzheimersday https://www.iqvia.com//alzheimers-on-the-threshold-of-chan

"IQVIA Institute for Human Data Science in a report from April 2018 finds that the balance of medicine spending has shifted strongly to specialty medicines, which drove $9.8 billion of the $12 billion net growth of new brands and now accounts for 46.5% of per-person, per-year spending on medicines. The biologic market grew by 12.6% in 2017, accounting for $11.5 billion in spending. IQVIA predicts over the next five years, 20% of the 40 to 45 new active substances projected to be launched each year will be next-generation biotherapeutics, such as cell-based therapies, gene therapies, and regenerative medicines with costs approaching $100,000." Read more: http://www.pharmavoice.com/article/2018-09-biologics/